Form 4: Mineralys Therapeutics Director Glenn Sblendorio Acquires 22,000 Stock Options
SEC Form 4 Filing
Director Glenn Sblendorio acquired 22,000 stock options in Mineralys Therapeutics, Inc. on May 22, 2024.
Summary
- Glenn Sblendorio, a director of Mineralys Therapeutics, Inc., acquired 22,000 stock options on May 22, 2024.
- The options have an exercise price of $12.52.
- The stock options vest in 12 substantially equal monthly installments beginning on June 22, 2024.
- Any remaining unvested portion of the stock option award will vest on the date of the next annual meeting of stockholders if it occurs before May 22, 2025.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a director's acquisition of stock options, which is a common form of executive compensation in the pharmaceutical industry.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of stock option grant |
| 05/22/2024 | Transaction date of the stock option acquisition. |
| 05/23/2024 | Date of Form 4 filing. |
| 06/22/2024 | Vesting start date for the stock options. |
| 05/22/2025 | Date before which any remaining unvested options will vest if the next annual meeting of stockholders occurs. |
| 05/22/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.